Home » Newsletters » BioWorld Science

BioWorld Science

May 7, 2013

View Archived Issues

Research indicates 1-dSLs as novel clinically relevant biomarkers of metabolic syndrome, diabetes

Vaccination with GI-13020 induces T-cell responses in mice

Portola Pharmaceuticals presents first-in-human results for PRT-064445

Redx Pharma licenses anticancer program from Pharmascience

Tauriga Sciences and Constellation Diagnostics to establish joint venture

Gilead Sciences profiles pipeline developments of first quarter 2013

Antibody-drug conjugate IMGN-289 targets EGFR in cancer cells

GSK profiles novel PERK inhibitor

Incyte Corp. presents new PKA and Akt inhibitors

Bristol-Myers Squibb designs new agents for thromboembolic disorders

Arena Pharmaceuticals prepares novel GPR119 receptor agonists

AbbVie obtains FDA breakthrough therapy designation for combination antiviral therapy

Data safety monitoring committee recommends completion of phase IIb aldoxorubicin trial

New serotonin receptor antagonists synthesized by UCB

Isis Pharmaceuticals begins phase Ib/IIa study of ISIS-STAT3Rx in liver cancer

Senesco begins cohort 3 in study of SNS01-T

Pfizer patents new autotaxin inhibitors

Osphena now available in U.S. pharmacies

Cadila Healthcare discloses novel JAK inhibitors

Kowa applies for approval to conduct phase I study of K-912

Allegro Ophthalmics presents first-in-human results for ALG-1001

Eisai submits European application to expand use of Halaven

Phase II study of RaQualia's acid pump antagonist begins in Korea

Concert Pharmaceuticals and Celgene form collaboration to develop deuterium-modified compounds

Array BioPharma describes planned global phase III trial of MEK-162

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...